Moleculin Biotec Stock Price, News & Analysis

Moleculin Biotech (Nasdaq: MBRX) announced its participation in the Virtual Investor Lunch Break: The Moleculin Opportunity event scheduled for June 12, 2024, at 12:00 PM ET. Walter Klemp, Chairman and CEO, will provide a corporate overview and business outlook. The event includes a live Q&A session where attendees can submit questions. A live webcast will be available on Moleculin's website, with a replay accessible for 90 days.

Moleculin Biotech (Nasdaq: MBRX) announced that its abstract has been accepted for a poster presentation at the European Hematology Association (EHA) 2024 Hybrid Congress. The event will take place from June 13-16, 2024, in Madrid, Spain, and virtually.

The presentation will focus on the study titled 'Liposomal Annamycin (L-ANN) in Combination with Cytarabine for Treatment of Patients with Acute Myeloid Leukemia (AML) Refractory to or Relapsed After Induction Therapy (MB-106 Study).'

The presenting author will be Dr. Wolfram C. M. Dempke, European Chief Medical Officer of Moleculin.

Moleculin Biotech has announced the start of a Phase 2 clinical trial evaluating WP1066 in combination with radiation therapy for glioblastoma, in collaboration with Northwestern University.

The trial, funded by the NIH and BrainUp, is aimed at improving treatment options for glioblastoma, which has a median survival rate of 15 months.

WP1066 has shown promise in animal models, demonstrating both therapeutic responses and immune 'memory' effects. This trial will focus on progression-free survival and tumor microenvironment analysis.

Moleculin's WP1066 is designed to activate immune responses and inhibit important oncogenic transcription factors involved in tumor survival and proliferation. The company has also received Orphan Drug Designation for WP1066 for brain tumors and Rare Pediatric Disease designation for other pediatric indications.

Moleculin Biotech, Inc., reported strong financial results for the first quarter of 2024. The company achieved a 62% CRc rate in 1st and 2nd line AML subjects with Annamycin in combination with Cytarabine. The MB-106 trial reached 20 subjects with a CRc rate of 45% in 1st – 7th line. The company also highlighted the positive interim data for Annamycin and announced the formation of the Annamycin Scientific Advisory Board. Financially, R&D expenses decreased due to clinical trials activity levels, while cash and cash equivalents stood at $16.8 million as of March 31, 2024.

Moleculin Biotech, Inc. announced the receipt of a U.S. Patent for Lipid-Based Delivery Technology for Annamycin, extending through 2040 with potential for further extensions. The drug Annamycin is moving towards a pivotal AML study in 2024, possibly qualifying for accelerated approval. The Company aims to establish a strong patent estate for Annamycin and drive its development forward, with promising results in clinical trials.

Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its Q1 2024 financial results on May 10, 2024. The company focuses on drug candidates for hard-to-treat tumors and viruses. A conference call and webcast to discuss the results will be held on May 13, 2024, at 8:30 AM ET.

Moleculin Biotech, Inc. reports positive interim data for Annamycin in treating acute myeloid leukemia (AML). The CRc rate reached 62% in 1st and 2nd line AML subjects, with a 45% CRc in the full MB-106 trial. The presentation of data supports advancing to a Phase 2 trial (MB-108) for potential New Drug Approval. A virtual AML Clinical Day was held on May 7, 2024. Key data shows promising results and progression towards registration for Annamycin in AML.

Moleculin Biotech, Inc. (Nasdaq: MBRX) will host a virtual AML Clinical Day featuring Dr. Martin Tallman, discussing the unmet medical needs in AML treatment, Annamycin, and the Company's AML clinical development program. The event will highlight the ongoing progress of Annamycin towards a pivotal AML study in 2024 for potential accelerated approval.

Moleculin Biotech, Inc. announced the formation of its Annamycin Scientific Advisory Board, appointing Dr. Martin Tallman as the inaugural clinician member. Dr. Tallman, an internationally renowned clinician, brings extensive experience in leukemia-targeting therapies. The company aims to advance the development of Annamycin, a promising treatment for AML and STS lung mets.